Baird Maintains an 'Outperform' on InterMune Inc. (ITMN); Incrementally Positive on Favorable Reimbursement Decision for Esbriet in Germany
Tweet
Share
E-mailGet Alerts ITMN Hot Sheet
Price: $73.89 --0%
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Baird maintains an 'Outperform' on InterMune Inc. (NASDAQ: ITMN) price target of $38.00.
Analyst, Thomas J. Russo, said, "The stock could trade up as much as 20+% on the decision finding that Esbriet has a benefit in mild-to-moderate IPF. G-BA's scoring of "4" for an non-quantifiable benefit supersedes and is better than the December IQWiG recommendation of "5" for no benefit and puts Esbriet back on track for more normal reimbursement negotiations. This relieves a sizable overhang and could/should return the stock to pre-December levels in our view."
"Conference call 4 p.m. EDT today. Heading in, we would not anticipate having to make any changes to our ITMN model. We'd remain buyers at least into the high teens near term, with positive bias and potentially very significant upside from there over the intermediate term if one considers the US opportunity with Phase 3 data coming mid-13."
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $14.80 yesterday.
Analyst, Thomas J. Russo, said, "The stock could trade up as much as 20+% on the decision finding that Esbriet has a benefit in mild-to-moderate IPF. G-BA's scoring of "4" for an non-quantifiable benefit supersedes and is better than the December IQWiG recommendation of "5" for no benefit and puts Esbriet back on track for more normal reimbursement negotiations. This relieves a sizable overhang and could/should return the stock to pre-December levels in our view."
"Conference call 4 p.m. EDT today. Heading in, we would not anticipate having to make any changes to our ITMN model. We'd remain buyers at least into the high teens near term, with positive bias and potentially very significant upside from there over the intermediate term if one considers the US opportunity with Phase 3 data coming mid-13."
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $14.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
- Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
